Francisco Partners, a leading technology-focused private equity firm, today announced that it has completed a strategic investment in Therapeutic Research Center, a leading provider of drug therapy recommendations, continuing education, training, and data to the healthcare community.
“We see a growing need for reliable information for healthcare professionals as advances in technology and a growing patient population combine to make the practice of medicine increasingly complex,” said Chris Adams, a principal with Francisco Partners. “Therapeutic Research Center is one of the most trusted platforms in healthcare, and we look forward to supporting the company in its continued growth.”
Founded in 1985, Therapeutic Research Center conducts extensive research to synthesize the frequently changing and often unclear data on drug therapy into clear, concise, and unbiased recommendations for medical professionals. The company offers a broad portfolio of drug therapy advisory services, including Pharmacist’s Letter, Prescriber’s Letter, and Pharmacy Technician’s Letter. The company also offers an extensive set of accredited continuing education programs.
“We founded Therapeutic Research Center with the mission of providing healthcare professionals with high-quality, unbiased information and recommendations that improve patient care and patient outcomes,” said Jeff Jellin, founder and editor-in-chief of Therapeutic Research Center. “Francisco Partners’ deep technology expertise will help us incorporate new technology and tools to better inform and educate healthcare professionals and help achieve our core mission.”
Shearman & Sterling LLP acted as legal advisor to Francisco Partners. Berkery, Noyes & Co. served as the financial advisor to Therapeutic Research Center, and Choate Hall and Stewart LLP provided legal counsel to the company.